Evidence map›Paper›PMID 40072067›Full record

ArticleCells2025

A

Andrea Spinaci, Michela Buccioni, Diego Dal Ben, Beatrice Francucci, Karl-Norbert Klotz, Gabriella Marucci, Nicola Simola, Micaela Morelli, Annalisa Pinna, Rosaria Volpini and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea SpinaciMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0002-5172-651X
Michela BuccioniMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0002-8383-0813
Diego Dal BenMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0002-6616-6885
Beatrice FrancucciMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0003-2082-6638
Karl-Norbert KlotzInstitut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Str. 9, D-97078 Würzburg, Germany.
Gabriella MarucciMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.
Nicola SimolaDepartment of Biomedical Sciences, Section of Neuroscience, University of Cagliari, Cittadella Universitaria, SP 8, Km 0.700, I-09042 Monserrato, Italy.ORCID 0000-0001-7296-3197
Micaela MorelliDepartment of Biomedical Sciences, Section of Neuroscience, University of Cagliari, Cittadella Universitaria, SP 8, Km 0.700, I-09042 Monserrato, Italy.
Annalisa PinnaNeuroscience Institute, National Research Council of Italy (CNR), Cagliari Cittadella Universitaria, SP 8, Km 0.700, I-09042 Monserrato, Italy.ORCID 0000-0002-4911-1735
Rosaria VolpiniMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0002-5304-5232
Catia LambertucciMedicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via Madonna delle Carceri, I-62032 Camerino, Italy.ORCID 0000-0003-2004-1531

Funding

MURST (Italian Ministry of Education, Universities and Research) RBNE03YA3L-2005Università di Camerino FAR 2019, grant number FPI000065
6 · The paper itself

Abstract

Parkinson's disease (PD) represents a growing challenge to global health, as it involves millions of people. The high grade of disability is due to the loss of dopaminergic neuron activity, and levodopa is the gold-standard therapy used to restore dopamine in the dopamine-denervated regions. Another therapeutic approach is the use of A

Indexed as

Adenosine A2 Receptor AntagonistsParkinson DiseaseReceptor, Adenosine A2AAnimalsAntiparkinson AgentsDisease Models, AnimalHumansLevodopaMaleOxidopaminePurinesRatsRats, WistarAdenosine A2 Receptor AntagonistsAntiparkinson AgentsistradefyllineLevodopaOxidopaminePurinesReceptor, Adenosine A2Aadenosine receptor antagonistsadenosine receptor ligandsbinding and functional assaysin vivo models of Parkinson’s diseasemedicinal chemistrysynthesis of purine derivatives

Identifiers

PMID40072067
PMCPMC11898488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.